# FDA 483 - Rafaelito S. Victoria, MD - September 25, 2020

Source: https://www.keypedia.com/records/483/rafaelito-s-victoria-md/99eef669-e2e8-49c8-bc30-665e6e035a5a

> FDA 483 for Rafaelito S. Victoria, MD on September 25, 2020. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Rafaelito S. Victoria, MD
- Inspection Date: 2020-09-25
- Product Type: drugs
- Office Name: Division of Pharmaceutical Quality Operations IV
- Summary: An FDA inspection of Rafaelito S. Victoria, MD in Anaheim, CA, revealed multiple deficiencies in the conduct of clinical investigations. The firm failed to report adverse events, adhere to the investigational plan, and maintain accurate case histories. Additionally, issues were noted with financial disclosure and informed consent procedures, indicating significant non-compliance with regulatory requirements for clinical trials.

## Related Documents

- [483 - 2022-06-10](https://www.keypedia.com/records/483/rafaelito-s-victoria-md/e7834225-596e-4ad2-8bb1-cc5b3a43b792)

## Related Officers

- [issuing_officer](https://www.keypedia.com/people/michelle-j-hines/c8087e41-6b8a-4b9a-92ad-bba500ce6fee)

Company: https://www.keypedia.com/companies/rafaelito-s-victoria-md/a79d9137-2b5c-456f-81d8-c276c5453c67

Office: https://www.keypedia.com/offices/division-of-pharmaceutical-quality-operations-iv/a2d2ff91-dc0f-433e-b91f-ca90ff8998b6